CANNABIS INDUCES A CLINICAL RESPONSE IN PATIENTS WITH CROHN’S DISEASE: A RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY
Clinical Gastroenterology & Hepatology, 2013
In the world’s first randomized, placebo-controlled, double-blinded study of its kind, Dr. Naftali and a team of researchers used Tikun Olam’s Erez strain to produce dramatic results, with 45% of Crohn’s patients achieving “complete remission” and over 90% achieving substantial improvement – with no side effects witnessed.

Key Results:

  • Complete remission (CDAI score <150) was achieved by 5 of the 11 patients in the cannabis group

  • Clinical response (decrease in CDAI score of >100) was observed in 10 of the 11 patients
    3 of the 11 patients were weaned from steroid dependency

  • The cannabis group reported significantly less pain, and improved appetite and quality of life